Data on effects of MGB on obesity-related co-morbidities are scarce. The metabolic syndrome is responsible for a high mortality in morbidly obese patients. In all reports, the type 2 diabetes (T2D) remission rate after MGB was between 80 and 90% at 2 years, and stable at 10 years, outperforming sleeve gastrectomy. Hypertension and hyperlipemia decreased between 70 and 80%. Severe OSA no longer required CPAP in more than 90% of the patients. Joint pain decreased also mainly, but vitamin D deficiency must be screened and supplemented. There are until now no data on the efficiency of the MGB on non-alcoholic fatty liver disease, but a recent article showed that MGB resulted in greater weight loss, with a transitional deterioration of several liver parameters in the first postoperative year, which was not associated with weight loss. In summary, MGB results in great improvement in dangerous obesity-related co-morbidities, such as T2DM, hyperlipemia, hypertension and joint pain, but requires continuing surveillance.
Mini-gastric bypass One anastomosis gastric bypass Co-morbidity Metabolic syndrome Obstructive sleep apnea NASH Joint pain Hyperlipemia Hypertension Type 2 diabetes
This is a preview of subscription content, log in to check access.
Chevallier JM, Arman GA, Guenzi M, et al. One thousand single anastomosis (omega loop) gastric bypasses to treat morbid obesity in a 7-year period: outcomes show few complications and good efficacy. Obes Surg. 2015;25:951–8.CrossRefPubMedGoogle Scholar
Guenzi M, Arman G, Rau C, Cordun C, Moskowicz D, Voron T, Chevallier JM. Remission of type 2 diabetes after omega loop gastric bypass for morbid obesity. Surg Endosc. 2015;29:2669–74.CrossRefPubMedGoogle Scholar
Kular KS, Manchanda N, Rutledge R. Analysis of the five-year outcomes of sleeve gastrectomy and mini-gastric bypass: a report from the Indian subcontinent. Obes Surg. 2014;24:1724–8.CrossRefPubMedGoogle Scholar
Musella M, Sousa A, Greco F, De Luca M, et al. The laparoscopic mini-gastric bypass: the Italian experience: outcomes from 974 consecutive cases in a multi-center review. Surg Endosc. 2014;28:156–63.CrossRefPubMedGoogle Scholar
Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC. Laparoscopic mini-gastric bypass: experience with tailored bypass limb according to body weight. Obes Surg. 2008;18:294–9.CrossRefPubMedGoogle Scholar
Musella M, Apers J, Rheinwalt K, et al. Efficacy of bariatric surgery in type 2 diabetes mellitus remission: the role of mini-gastric bypass and sleeve gastrectomy at 1 year follow up: a European survey. Obes Surg. 2016;26:933–40.CrossRefPubMedGoogle Scholar
Lee W-J, Chong K, Lin YH, Wei JH, Chen SC. Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect. Obes Surg. 2014;24:1552–62.CrossRefPubMedGoogle Scholar
Klebanoff MJ, Corey KE, Chhatwal J, et al. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology. 2017;65:1156–64.CrossRefPubMedGoogle Scholar
Kruschitz R, Luger M, Klenbacher C, et al. The effect of Roux-en-Y vs omega-loop gastric bypass on liver, metabolic parameters and weight loss. Obes Surg. 2016;26:2204–12.CrossRefPubMedPubMedCentralGoogle Scholar
Lee W-J, Ser KH, Lee YC, Tsou JJ, Chen SC, Chen JC. Laparoscopic Roux-en-Y vs mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obes Surg. 2012;22:1827–34.CrossRefPubMedGoogle Scholar
Luger M, Kruschitz R, Langer F, Prager G, Walker M, et al. Effects of omega-loop gastric bypass on vitamin D and bone metabolism in morbidly obese bariatric patients. Obes Surg. 2015;25:1056–62.CrossRefPubMedGoogle Scholar
Bruzzi M, Voron T, Chevallier JM, et al. Revisional single-anastomosis gastric bypass for a failed restrictive procedure: 5-year results. Surg Obes Relat Dis. 2016;12:240–5.CrossRefPubMedGoogle Scholar